Protein Kinase Inhibitors: all 15,278 studies that test it

Page 45 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect InvestigationCompletedNCT02310750Phase 1Results posted
• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.CompletedNCT02310321Phase 1/2Results posted
• A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedNCT02308163Phase 3Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedNCT02305849Phase 3Results posted
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin LymphomaCompletedNCT02303392Phase 1Results posted
• Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell CarcinomaTerminatedNCT02303041Phase 2Results posted
• Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by SurgeryCompletedNCT02302833Phase 2Results posted
• A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast CancerCompletedNCT02301988Phase 2Results posted
• Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)CompletedNCT02301364Phase 2Results posted
• A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent ProgressionCompletedNCT02300987Phase 2Results posted
• Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for ChemotherapyCompletedNCT02300545Phase 2Results posted
• Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line ChemotherapyCompletedNCT02300298Phase 1Results posted
• A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver DamageCompletedNCT02300025Phase 1Results posted
• Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02299375Phase 2Results posted
• Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And UniversalisCompletedNCT02299297Phase 2Results posted
• Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02299141Phase 2Results posted
• A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedNCT02297438Phase 3Results posted
• Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibCompletedNCT02297139Phase 2Results posted
• A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast CancerCompletedNCT02296801Phase 2Results posted
• Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesCompletedNCT02296242Phase 1/2Results posted
• Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsCompletedNCT02296112Phase 2Results posted
• Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedNCT02294786Phase 2Results posted
• An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseCompletedNCT02294734Phase 2Results posted
• Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCompletedNCT02293005Phase 2Results posted
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.CompletedNCT02292446Phase 3Results posted
• Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results posted
• A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results posted
• Study of MEK162 for Children With Low-Grade GliomasCompletedNCT02285439Phase 1/2Results posted
• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester DiseaseCompletedNCT02281760Phase 2Results posted
• A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid ArthritisCompletedNCT02281552Phase 3Results posted
• A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaCompletedNCT02279719Phase 1/2Results posted
• Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube CancerTerminatedNCT02278783Phase 2Results posted
• First in Human Study of M4344 in Participants With Advanced Solid TumorsCompletedNCT02278250Phase 1Results posted
• Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT02278120Phase 3Results posted
• Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal CancerTerminatedNCT02277093Phase 2Results posted
• A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
• Phase 1 Study of E7090 in Subjects With Solid TumorCompletedNCT02275910Phase 1Results posted
• A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)CompletedNCT02273973Phase 2Results posted
• Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2Results posted
• BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid TumoursCompletedNCT02273388Phase 1Results posted
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the LiverCompletedNCT02273362Phase 1/2Results posted
• Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.CompletedNCT02272998Phase 2Results posted
• A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
• Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell LymphomaTerminatedNCT02272686Phase 2Results posted
• The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant SettingTerminatedNCT02271906Phase 2Results posted
• Phase II Study of Everolimus Beyond ProgressionTerminatedNCT02269670Phase 2Results posted
• The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedNCT02269267Phase 2Results posted
• A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedNCT02268851Phase 1Results posted
• Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedNCT02267278Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)CompletedNCT02265705Phase 3Results posted
• An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedNCT02265510Phase 1/2Results posted
• Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 FusionsCompletedNCT02265341Phase 2Results posted
• A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)CompletedNCT02264574Phase 3Results posted
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• A Study of Baricitinib in Healthy Japanese ParticipantsCompletedNCT02263911Phase 1Results posted
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results posted
• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory LymphomaCompletedNCT02259010Phase 1Results posted
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaTerminatedNCT02258529Phase 2Results posted
• BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT02257541Phase 1/2Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• A Study of LY2835219 in Healthy ParticipantsCompletedNCT02256267Phase 1Results posted
• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsTerminatedNCT02255461Phase 1Results posted
• A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development ProgramCompletedNCT02251938Phase 3Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerActive, not recruitingNCT02246621Phase 3Results posted
• Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine TumorCompletedNCT02246127Phase 3Results posted
• A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerCompletedNCT02244463Phase 1/2Results posted
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaActive, not recruitingNCT02243605Phase 2Results posted
• Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT02242097Phase 2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
• Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI CancersTerminatedNCT02241720Phase 2Results posted
• A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.CompletedNCT02238782Phase 1Results posted
• A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance TherapyCompletedNCT02238483Phase 2Results posted
• Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk ScoreTerminatedNCT02236572Phase 2Results posted
• A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerCompletedNCT02236000Phase 1/2Results posted
• A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCompletedNCT02234986Phase 2Results posted
• Nintedanib in Patients With Advanced Esophagogastric CancerCompletedNCT02234596Phase 2Results posted
• Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and SurgeryTerminatedNCT02234180Phase 2Results posted
• Selonsertib in Adults With Pulmonary Arterial HypertensionCompletedNCT02234141Phase 2Results posted
• LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchTerminatedNCT02231164Phase 3Results posted
• Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesTerminatedNCT02230306Phase 2Results posted
• Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial CancerCompletedNCT02228681Phase 2Results posted
• Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase InhibitorsTerminatedNCT02228382Phase 4Results posted
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results posted
• Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy VolunteersCompletedNCT02224053Phase 1Results posted
• Crizotinib in High-Risk Uveal Melanoma Following Definitive TherapyCompletedNCT02223819Phase 2Results posted
• Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular DegenerationTerminatedNCT02222207Phase 2Results posted
• A Study of BKM120 (Buparlisib) in Relapsed or Refractory ThymomasCompletedNCT02220855Phase 2Results posted
• Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate CancerCompletedNCT02215096Phase 1Results posted
• Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic FunctionCompletedNCT02214147Phase 1Results posted
• An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaActive, not recruitingNCT02213926Phase 2Results posted
• Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02213042Phase 2Results posted
• Evaluation of Votrient in AngiosarcomaTerminatedNCT02212015Phase 2Results posted
• An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1Results posted
• Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT02208843Phase 4Results posted

← Protein Kinase Inhibitors overview